Original Article

Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy

Hyunseong Kim†, Gihyun Lee†, Sung-Hwa Sohn†, Chanju Lee, Jung Won Kwak, and Hyunsu Bae*

Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea

ARTICLE INFO
Received November 7, 2015
Revised January 15, 2016
Accepted March 14, 2016

*Correspondence
Hyunsu Bae
E-mail: hbae@khu.ac.kr

Key Words
Cisplatin
EL4 lymphoma
Immunotherapy
Methyl gallate
Regulatory T cell

†These authors contributed equally to this work.

ABSTRACT Foxp3+ CD25+ CD4+ regulatory T (Treg) cells are crucial for the maintenance of immunological self-tolerance and are abundant in tumors. Most of these cells are chemo-attracted to tumor tissues and suppress anti-tumor responses inside the tumor. Currently, several cancer immunotherapies targeting Treg cells are being clinically tested. Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment. While cisplatin is a powerful drug for the treatment of multiple cancers, there are obstacles that limit its use, such as renal dysfunction and the development of cisplatin-resistant cancer cells after its use. To minimize these barriers, combinatorial therapies of cisplatin with other drugs have been developed and have proven to be more effective to treat cancer. In the present study, we evaluated the effect of the combination therapy using methyl gallate with cisplatin in EL4 murine lymphoma bearing C57BL/6 mice. The combinatorial therapy of methyl gallate and cisplatin showed stronger anti-cancer effects than methyl gallate or cisplatin as single treatments. In Treg cell-depleted mice, however, the effect of methyl gallate vanished. It was found that methyl gallate treatment inhibited Treg cell migration into the tumor regardless of cisplatin treatment. Additionally, in both the normal and cisplatin-treated tumor-bearing mice, there was no renal toxicity attributed to methyl gallate treatment. These findings suggest that methyl gallate treatment could be useful as an adjuvant method accompanied with cisplatin therapy.

INTRODUCTION

Regulatory T (Treg) cells, which express the transcription factor Foxp3, are present in the immune system and are actively engaged in the maintenance of immunological self-tolerance by suppressing self-reactive T cells [1,2]. They are found at high frequencies in the tumor tissues of various types of cancers, such as breast, lung, liver, pancreatic and gastrointestinal. This subset of T-cells hampers effective anti-tumor immune responses in cancer patients, and these cells can be used as a cellular target to evoke and augment anti-tumor immunity [3,4].

Cisplatin is commonly used as a chemotherapeutic agent. It clinically displays activity against a wide variety of solid tumors including ovarian, head and neck, and germ cell tumors. However, it does have adverse reactions, such as nephrotoxicity and a drug-resistant phenotype, and these reactions radically limit the clinical utility of cisplatin [5,6]. Recent studies have shown that the combination therapy of cisplatin with other drugs may be more effective for cancer treatment due to reduced side effects [7-9].

In a previous study, we reported that the treatment of murine tumors with methyl gallate extracted from Moutan Cortex Radicis exerted antitumor effects. In tumor-bearing animals, treatment with methyl gallate delayed tumor progression...
and prolonged survival through the inhibition of the tumor infiltration activity of Foxp3\(^+\) Treg cells [2]. It was shown that methyl gallate treatment could be used as a potentially useful adjuvant for enhancing the efficacy of anti-cancer therapy by reversing immune suppression. It is envisaged that combinations of methyl gallate, which reduces Treg cells in tumor tissues, with cisplatin, which is antineoplastic drug, may make current cancer therapies more effective. Here, we investigated whether methyl gallate treatment augmented the anti-cancer effect of cisplatin.

**METHODS**

**Material**

Methyl gallate was purchased from ChromaDex (purity 96% minimum; Irvine, CA, U.S.) and dissolved in distilled water for 10 mg/ml stock. Stock stored in –20°C was freshly diluted right before use. Cisplatin was purchased from Sigma-Aldrich (St. Louis, MO, U.S.) and dissolved in normal saline. For Treg depletion, anti-mouse CD25 rat IgG1 (anti-CD25, clone PC61) antibodies were generated in our laboratory from hybridomas obtained from the American Type Culture Collection (Manassas, VA, U.S.). Fluorescence conjugated antibodies for CD3, CD4, CD19, and CD25 detection are purchased from eBioscience (San Diego, CA, U.S.).

**Mice**

C57BL/6 mice (5~6 weeks of age, weighing 17~20 g) were purchased from Charles River Korea (Seungnam, Seoul, South Korea). Foxp3\(^{EGFP}\)C57BL/6 (C.Cg-Foxp3tm2Tch/J) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, U.S.). All mice were kept under specific pathogen-free conditions with air conditioning and a 12 h light/dark cycle. All animal experiments were approved by the Animal Care and Use Committee of Kyung Hee University (KHUASP(SE)-11-033).

**EL4 mouse lymphoma cell culture**

Mouse EL4 lymphoma (EL4) cells (KCLB 40039; Cancer Research Institute, Seoul, Korea) were cultured in DMEM (Welgene) with 10% FBS (HyClone, Logan, UT) and 1% penicillin-streptomycin (Invitrogen). EL4 cells were treated various doses of methyl gallate (0~50 µg/µl) or cisplatin (0~10 µg/µl). To measure the cell cycle, EL4 cells (2×10\(^6\) cells/well) were plated in 6-well culture plates and incubated for 24 h in a CO\(_2\) incubator. The cells were fixed with 70% ethanol at 4°C overnight and then incubated with propidium iodide (PI, 0.05 mg/ml) containing RNase (2 mg/ml) for 30 min in the dark. The cells were analyzed by flow cytometry (FACS Caliber, BD Biosciences, U.S.A.). To measure the viability of the cells, EL4 cells (1×10\(^6\) cells/well) were plated in 24-well culture plates, and MTS (20 µl/well) was added to the medium after 24 h.

**Immune cell and renal toxicity analysis**

Foxp3\(^{EGFP}\) mice were injected with saline or methyl gallate (20 mg/kg) once a day for 5 days. Isolated splenocytes were stained with anti-CD4 APC and anti-CD25 PE or anti-CD19 APC and anti-CD3 PE antibodies (eBioscience). After gating CD4\(^+\) cells, the CD25\(^+\)Foxp3\(^+\) cells were measured using flow cytometry and the FlowJo software (Treestar, U.S.) for the analysis of Treg cells. To analyze renal toxicity, serum was obtained from each mouse. Blood samples were left at room temperature for 1 hour and then centrifuged at 1,000 g for 10 min. The serum creatinine and BUN levels were measured using a FUJI DRI-CHEM 3500i instrument (Fujifilm Photo LTD., Japan).

**Tumor inoculation and drug administration**

On day 0, C57BL/6 and Foxp3\(^{EGFP}\)C57BL/6 mice were inoculated s.c. in the right flank with 5×10\(^4\) EL4 cells. To induce the depletion of Treg cells, anti-CD25 Abs (hybridoma clone PC61; 500 µg/mouse) were administered i.p. on days 3, 9, and 15. On day 5 after tumor inoculation, methyl gallate (20 mg/kg, every other day) or cisplatin (1 mg/kg, on days 5, 11, and 17) was injected i.p. The control groups were given saline as a vehicle according to their compared groups. The tumors were measured using two perpendicular diameters every other day, and the volume was then calculated using the following formula:

\[
\text{Volume} = \frac{\pi}{6} \times d_1^2 \times d_2 \quad (\text{if } d_1 < d_2)
\]

**Confocal microscopy image analysis**

To visualize and quantify the degree of migration of the Treg cells into the tumor, lymphoma tissues from Foxp3\(^{EGFP}\)C57BL/6 mice were fixed in 4% paraformaldehyde overnight and then in 30% sucrose in PBS for 2 days. Then, the fixed-tumor tissues were embedded in Tissue-Tek O.C.T. compound, frozen, and then sliced into 20-µm sections using a cryostat. The samples were analyzed with a LSM 5 PASCAL confocal laser-scanning microscope system (Carl Zeiss SMT, Berlin, Germany). The numbers of EGFP-positive cells were counted in three lymphoma sections.

**Statistical analysis**

All results are expressed as the mean±S.E.M. and were analyzed using a one-way ANOVA with Tukey's post-hoc test. The differences were considered to be significant at p<0.05.
RESULTS

Methyl gallate treatment enhances the anti-cancer effect of cisplatin

To elucidate the effect of the combination therapy of methyl gallate and cisplatin, either or both compounds were used to treat the C57BL/6 mice with established subcutaneous EL-4 lymphoma. Treatment with methyl gallate or cisplatin showed an anti-tumor growth effect. The combination therapy of methyl gallate and cisplatin exhibited a significantly greater effect on anti-tumor growth than methyl gallate or cisplatin as a single treatment (Fig. 1; tumor weight: saline: 5.72±0.69 g, methyl gallate: 3.99±0.25 g, cisplatin: 3.76±0.34 g, methyl gallate+cisplatin: 2.36±0.34 g on day 21). This finding indicates that methyl gallate has an anti-tumor effect and that its mechanism does not hinder the effect of cisplatin.

Treg cell infiltration into tumor tissue was inhibited by methyl gallate treatment

To confirm the effect of methyl gallate on Treg cell migration, confocal microscopy was used to inspect cryosectioned tumor tissue from Foxp3EGFP mice sacrificed at day 21 after tumor inoculation. The number of Foxp3-positive cells was significantly decreased in the tumors of the methyl gallate treated mice when compared with the number of positive cells in the tumor tissues of the non-methyl gallate treated controls (Fig. 2). Infiltrated Treg cell number: saline: 32.30±5.61, methyl gallate: 12.80±1.02, cisplatin: 33.88±3.50, methyl gallate+cisplatin: 15.92±2.11). These results indicate that the methyl gallate treatment blocked the migration of Treg cells, which suppressed anti-tumor response in tumor.

Fig. 1. Methyl gallate treatment enhances the anti-tumor effect of cisplatin therapy. All mice received injections of EL4 cells (5x10^4/0.1 ml) s.c. into the right flank. Methyl gallate (20 mg/kg) was injected i.p. every other day for 14 days from day 5 of tumor inoculation (n=10). Cisplatin (1 mg/kg) was injected i.p. 3 times (on days 5, 11 and 17). All mice were sacrificed at day 21, and the tumor was fully separated from the mice and weighed. The results represent the means±SEM. *p<0.05, **p<0.01, ***p<0.001 vs. each respective saline-treated control. #p<0.05 vs. indicated control. MG, methyl gallate; Cis, cisplatin; MG+Cis, methyl gallate+cisplatin.

Fig. 2. Methyl gallate treatment inhibits the migration of Treg cells into tumors. Foxp3EGFP C57BL/6 Treg cells were detected in tumors using EGFP signal detected with confocal microscope imaging. The results are presented as the mean±SEM. *p<0.05, **p<0.01 vs. each respective saline-treated control. #p<0.05 vs. indicated control. MG, methyl gallate; Cis, cisplatin; MG+Cis, methyl gallate+cisplatin.
The anti-tumor effect of methyl gallate vanished in Treg cell depleted mice

In a previous report, we found that the anti-tumor activity of methyl gallate was related to Treg cells. To confirm the Treg cell mediated anti-tumor effect of methyl gallate, we treated Treg cell-depleted tumor-bearing mice with methyl gallate or/and cisplatin. The Treg cells were depleted with the anti-CD25 antibody (PC61) in tumor-bearing mice. As expected, in Treg cell-depleted mice, the tumor growth was slower than in wild type mice with vehicle treatment. Cisplatin inhibited the tumor growth of both the Treg cell-depleted and wild type mice, but the methyl gallate treatment lost its anti-tumor effect in the Treg cell-depleted mice (Fig. 3). This result confirms that Treg cells are necessary for the anti-tumor effect of methyl gallate.

Methyl gallate has no effect on EL4 cell cycle and viability

To determine whether methyl gallate has a direct anti-tumor effect on EL4 cells, we conducted an in vitro tumor cell cycle analysis and a viability test using various concentrations of methyl gallate (0~50 µg/ml). The cisplatin treatment resulted in G1 arrest (% of sub G1 phase: PBS: 2.55±0.90, methyl gallate: 4.98±0.42, cisplatin: 26.86±0.43) and cell death, but the methyl gallate treatment showed no effect on the cell cycle or the viability (Fig. 4). These results suggest that methyl gallate controlled tumor growth indirectly.

Methyl gallate did not effect on population of T cells, B cells, and Treg cells in spleen

To determine whether methyl gallate affected the proportions of immune cells, we measured the T cell, B cell, and Treg cell populations of the spleen in methyl gallate treated mice. As a result, there was no significant change in the ratio of CD3⁺ T cells, CD19⁺ B cells, and CD4⁺ Foxp3⁺ Treg cells compared with the ratio of the vehicle treated mice (Fig. 5).

Methyl gallate does not increase renal toxicity

To probe the nephrotoxicity of methyl gallate, we measured the levels of serum creatinine and BUN in normal mice after methyl gallate injections once a day for 5 days. The results showed that the methyl gallate injections did not alter the serum creatinine level.
The effects of methyl gallate on cisplatin therapy

Fig. 5. Methyl gallate has no effect on immune cell proportions in the spleen. Splenocytes were prepared from Foxp3\textsuperscript{EGFP} mice injected with methyl gallate (20 mg/kg, every day for 5 days). The cells were stained with anti-CD3, anti-CD4, and anti-CD19 antibodies for 30 minutes on ice. The results are presented as the mean±SEM. NS, not significant vs. each respective saline-treated control. MG, methyl gallate.

Fig. 6. Methyl gallate does not cause renal toxicity. (A, B) The serum levels of creatinine and BUN were measured in the normal mice injected with methyl gallate (20 mg/kg) for 5 days everyday (n=5). (C, D) The mice received injections of EL4 cells (5×10\textsuperscript{4}/0.1 ml) s.c. into the right flank. Methyl gallate (20 mg/kg) was injected every other day for 14 days from day 5 of the tumor inoculation (n=10). Cisplatin (1 mg/kg) was injected 3 times (on days 5, 11 and 17). The level of creatinine and BUN were measured in the serum. The results are presented as the mean±SEM. *p<0.05, **p<0.001 vs. each respective saline-treated control. NS, not significant; MG, methyl gallate; Cis, cisplatin; MG+Cis, methyl gallate+cisplatin.
and BUN levels in normal mice. Next, we measured the serum creatinine and BUN levels after methyl gallate or/and cisplatin treatment in tumor bearing mice. The treatment with methyl gallate or/and cisplatin did not affect the level of serum creatinine and BUN in our study (Fig. 6).

**DISCUSSION**

It has become evident that the immune-suppressive elements present in cancer patients are critical impediments to the success of cancer immunotherapy [10-13]. One of the obstacles is that Treg cells, which are physiologically present in the immune system, are actively engaged in the maintenance of immunological self-tolerance by suppressing self-reactive T cells [4]. This T cell subset hampers effective anti-tumor immune responses in cancer patients, and because of this, they are thought to be one of the cellular targets that could be utilized to evoke and augment anti-tumor immunity. Indeed, Treg cells are found at high frequencies in tumor tissues from various types of cancers, such as breast, lung, liver, pancreatic and gastrointestinal cancers and malignant melanoma [3].

Immunotherapies targeting the depletion or functional alteration of Treg cells have been studied, but the clinical benefits are still unclear. The administration of the cell-depleting anti-CD25 monoclonal antibody resulted in tumor eradication in animal models [14,15]. Denileukin diftitox is a recombinant fusion protein product of diphtheria toxin and IL-2 that selectively binds to the IL-2 receptor of cells and, following internalization, inhibits protein synthesis. In a clinical study, denileukin diftitox was used to deplete Treg cells. Denileukin diftitox is the subject of numerous clinical trials, but to date, it fails to realize its clinical promise. Because CD25 is expressed on activated effector T cells, denileukin diftitox may also restrain protective antitumor immune responses. Rasku et al. demonstrated that denileukin diftitox depleted various subsets of T cells, including tumor antigen-specific CD8 T cells [16]. Tremelimumab, the anti-CTLA4 antibody, promotes anti-tumor response. However, Khan et al. reported that these results come from effector T cell activation rather than the modulation of Treg cells [17]. Moreover, a Phase III randomized clinical trial with tremelimumab failed to demonstrate a statistically significant survival advantage of the treatment with tremelimumab over the standard-of-care chemotherapy (temozolomide or dacarbazine) in first-line treatment of patients with metastatic melanoma [18].

A new approach is desirable, as Treg cell depletion leads to an increase in the tumor-mediated effector T cell to Treg cell conversion with a diminution in anti-tumor immune responses [19]. It is agreed that a new approach should selectively modulate Treg cells within the tumor microenvironment, rather than their global depletion to minimize the risk of autoimmune manifestations. Notably, we found that methyl gallate extracted from Moutan Cortex Radicis displays a strong anti-tumor effect through disrupting the tumoral homing of Treg cells [2]. In the line with the thought that immunotherapy can complement anti-cancer chemotherapy [20-23], here, we studied the effect of the combination therapy of methyl gallate with cisplatin. Indeed, it was found that methyl gallate augmented the anti-cancer effect of cisplatin. In methyl gallate treated mice, tumor infiltration was decreased, while there was no difference in cisplatin treated mice. Methyl gallate treatment did not influence on the global population of T cells, B cells, or Treg cells. It was confirmed that the effect of methyl gallate was Treg cell dependent using a Treg cell depleted model.

In Treg cell tissue trafficking, distinct chemokine receptors and integrin molecules implicated [24,25]. CXCR4 mediates Treg cell bone marrow trafficking through bone marrow-derived CXCL12. The lymphoid homing molecules CCR7 and CD62L may facilitate lymphoid homing of Treg cell. CCR2, CCR5, and integrins may mediate Treg cell trafficking into inflammatory tissues. For Treg cell migration into tumor tissue, expression of CCR4 is responsible. CCR4 mediated Treg cell trafficking into human ovarian cancer [26], and Hodgkin lymphoma [27]. Previously, methyl gallate treatment down-regulated CCR4 expression on Treg cells in vitro [2]. Alternatively, there is a report showing CCR5 dependent homing of Treg cell to pancreatic tumor [28].

To elucidate the exact role of methyl gallate on Treg trafficking, further study using chemokine receptor knockout mice is needed. Some plant polyphenols induce antioxidant and anticancer activities, including cancer cell cycle arrest and apoptosis [29]. Recently, two gallic acid-derived compounds isolated from Casarea sylvestris, isobutyl gallate-3,5-dimethyl ether and methyl gallate-3,5-dimethyl ether, showed anti-tumor potential [30]. In the current study, we investigated the influences of methyl gallate on the EL4 cell cycle and cell viability. The results showed that methyl gallate had no effect on the cancer cell cycle or cell viability, while cisplatin arrested its cell cycle in the G0/G1 phase and showed strong cytotoxicity in cancer cells. Moreover, methyl gallate did not cause renal toxicity in normal and tumor bearing mice. However, a long-term toxicity study is needed to confirm this result for clinical applications. Additionally, the potentially adverse effect methyl gallate may have on the regulation of Treg cells should be studied.

In tumors, Treg cells not only dampen the anti-tumor process through their interaction with tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) but also promote tumor angiogenesis. Facciabene et al. demonstrated that Treg cell recruitment has a key role in establishing the vascular endothelial growth factor A (VEGFA)-rich tumor microenvironment and increasing tumor angiogenesis, whereas the depletion of Treg cells reduces tumor VEGFA levels and tumor vascularization [31]. Although Treg cells can contribute directly to the excessive production of VEGFA and can support endothelial cell recruitment and expansion, other tolerogenic
leukocyte populations, such as MDSCs, also produce VEGFA and support tumor angiogenesis [32,33]. MDSCs exert suppressive functions and regulate T cell responses through nitric oxide, reactive oxygen species and TGF-β secretion, and they also promote the induction of Treg cells and favor anti-inflammatory responses [34,35]. In the advanced tumor microenvironment, TAMs polarize to type 2 macrophage cells, releasing factors that encourage Th2 differentiation and recruitment [36]. They express a distinct set of cytokines and chemokines, including CCL17, CCL22 and CCL24, favoring the recruitment and development of Treg cells. Further studies probing the effects of methyl gallate on TAMs, MDSCs, and angiogenesis are needed.

In summary, in this study, we provide the first evidence that methyl gallate treatment enhances the antitumor effects of cisplatin therapy, which was mediated through the disruption of the tumoral homing of Treg cells, in a murine tumor model. Therefore, a combination treatment of methyl gallate and cisplatin could be used as an approach to potentiate anti-tumor effects.

**ACKNOWLEDGMENTS**

This work was supported by Kyung Hee University grant (No. 20110690) and the National Research Foundation of Korea (NRF) grant funded by the Korean government [MEST] (No. 2011-006220).

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**REFERENCES**

1. Campbell DJ. Control of regulatory T cell migration, function, and homeostasis. *J Immunol*. 2015;195:2507-2513.
2. Lee H, Lee H, Kwon Y, Lee JH, Kim J, Shin MK, Kim SH, Bae H. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells. *J Immunol*. 2010;185:6698-6705.
3. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Curr Opin Immunol*. 2014;27:1-7.
4. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. *Front Immunol*. 2013;4:190.
5. Karasawa T, Steger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. *Toxicol Lett*. 2015;237:219-227.
6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur J Pharmacol*. 2014;740:364-378.
7. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. *Mol Ther Nucleic Acids*. 2013;2:e110.
8. Kim YH, Choi BK, Kim KH, Kang SW, Kwon BS. Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. *Cancer Res*. 2008;68:7264-7269.
9. Lyass O, Hubert A, Gabizon AA. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. *Clin Cancer Res*. 2001;7:3040-3046.
10. Dougan M, Dranoff G. Immune therapy for cancer. *Annu Rev Immunol*. 2009;27:83-117.
11. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. *Int J Cancer*. 2010;127:759-767.
12. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. *Nat Rev Cancer*. 2011;11:805-812.
13. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol*. 2006;6:295-307.
14. Son CH, Bae JH, Shin DJ, Lee HR, Jo WS, Yang K, Park YS. Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer. *Int J Radiat Oncol Biol Phys*. 2015;92:390-398.
15. Chen L, Zhou S, Qin J, Hu H, Ma H, Liu B, Wang X, Ma J, Ye S, Zhong C, Zhou G, Liang C. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. *Mol Cancer*. 2013;12:153.
16. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Kramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Transient T cell depletion causes regression of melanoma metastases. *J Transl Med*. 2008;6:12.
17. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. *Clin Immunol*. 2011;138:85-96.
18. Ribas A, Kefferd R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachtner J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Rackow EC, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol*. 2013;31:616-622.
19. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nat Rev Cancer*. 2007;7:880-887.
20. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Lear SC, Piconese S. Regulatory-T-cell inhibition versus depletion causes regression of melanoma metastases. *Eur J Immunol*. 2009;39:336-344.
21. Lake RA, Robinson BW. Immunotherapy and chemotherapy--a practical partnership. *Nat Rev Cancer*. 2005;5:397-405.
22. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. *Cancer Res*. 2003;63:4490-4496.
23. van der Most RG, Robinson BW, Lake RA. Combining immunotherapy with chemotherapy to treat cancer. *Discov Med*. 2005;5:265-270.
24. Ding Y, Xu J, Bromberg JS. Regulatory T cell migration during an immune response. *Trends Immunol*. 2012;33:174-180.
25. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. *Blood*. 2006;108:426-431.

26. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burrow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*. 2004;10:942-949.

27. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. *Cancer Res*. 2006;66:5716-5722.

28. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. *J Immunol*. 2009;182:1746-1755.

29. Lizárraga D, Touriño S, Reyes-Zurita FJ, de Kok TM, van Delft JH, Maas LM, Briedé JJ, Centelles JJ, Torres JL, Cascante M. Witch hazel (Hamamelis virginiana) fractions and the importance of gallate moieties--electron transfer capacities in their antitumoral properties. *J Agric Food Chem*. 2008;56:11675-11682.

30. Da Silva SL, Chaar Jda S, Yano T. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae). *Eur J Pharmcol*. 2009;608:76-83.

31. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature*. 2011;475:226-230.

32. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. *Nat Biotechnol*. 2007;25:911-920.

33. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matsrian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell*. 2004;6:409-421.

34. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends Immunol*. 2011;32:19-25.

35. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol*. 2009;9:162-174.

36. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res*. 2010;70:5728-5739.